NFKB1 and primary cutaneous T-cell non-Hodgkin lymphoma: The suppression of the NF-κB pathway, which is abnormally activated in neoplastic cells and promotes their survival, migration, invasion, and resistance to chemotherapy, appears to be a crucial property of DMF in counteracting various types of cancer, including breast cancer and cutaneous T-cell lymphoma (CTCL) [22].